These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8337137)

  • 1. Therapeutic value of interleukin-3 given alone or in combination with other cytokines.
    Ganser A; Hoelzer D
    Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):245-6. PubMed ID: 8337137
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical use of hematopoietic growth factors].
    Robak T
    Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):365-8. PubMed ID: 1279638
    [No Abstract]   [Full Text] [Related]  

  • 3. Interleukin 3 and interleukin 3/GM-CSF combination therapy--clinical implications.
    Ganser A; Ottmann OG; Hoelzer D
    Stem Cells; 1993 Nov; 11(6):465-73. PubMed ID: 8111306
    [No Abstract]   [Full Text] [Related]  

  • 4. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
    Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
    Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
    Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
    Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of growth factors in severe aplastic anaemia (SAA).
    Hinterberger W; Hoffmann S; Bettelheim P; Geissler K; Maurer D; Muhm M
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():129-30. PubMed ID: 2697425
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical use of hematopoietic growth factors].
    Krusius T
    Duodecim; 1990; 106(7):547-9. PubMed ID: 1727024
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe idiopathic congenital aplastic anemia: role of hematopoietic growth factors.
    Vermylen C; Cornu G; DeWitte M; Heremans MT; Ninane J; Brichard B
    Bone Marrow Transplant; 1993 Oct; 12(4):413-5. PubMed ID: 8275043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical application of new cytokines].
    Kitamura K
    Rinsho Byori; 1993 Apr; 41(4):390-8. PubMed ID: 8350499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes.
    Ganser A; Hoelzer D
    Semin Hematol; 1996 Jul; 33(3):186-95. PubMed ID: 8819229
    [No Abstract]   [Full Text] [Related]  

  • 12. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Cazzola M
    Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Increase of neopterin after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF)].
    Melichar B; Solichova D; Jebavy L
    Presse Med; 1994 Mar; 23(12):581. PubMed ID: 8066063
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trials of granulocyte-macrophage colony-stimulating factor for the treatment of aplastic anemia.
    Vadhan-Raj S
    Immunol Ser; 1992; 57():661-70. PubMed ID: 1504150
    [No Abstract]   [Full Text] [Related]  

  • 15. Granulocyte-macrophage colony-stimulating factor.
    Devereux S; Linch DC
    Biotherapy; 1990; 2(4):305-13. PubMed ID: 2148492
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical use of growth factors in the myelodysplastic syndromes.
    Stein RS
    Am J Med Sci; 1994 May; 307(5):360-7. PubMed ID: 7513498
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of granulocyte colony-stimulating factor for treatment of aplastic anemia.
    Kojima S
    Nagoya J Med Sci; 1999 Nov; 62(3-4):77-82. PubMed ID: 10689869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of interleukin-3 on responsiveness to granulocyte-colony-stimulating factor in severe aplastic anemia.
    Geissler K; Forstinger C; Kalhs P; Knöbl P; Kier P; Kyrle P; Lechner K
    Ann Intern Med; 1992 Aug; 117(3):223-5. PubMed ID: 1377461
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine-mobilized peripheral blood progenitor cells.
    Nemunaitis J
    Semin Oncol; 1996 Apr; 23(2 Suppl 4):9-14. PubMed ID: 8600547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.